Maravai LifeSciences Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders
September 07 2021 - 4:10PM
Maravai LifeSciences Holdings, Inc.
(Maravai) (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, today announced the commencement of a public offering
of its Class A common stock by certain selling stockholders. The
selling stockholders are offering 20,000,000 shares of Maravai’s
Class A common stock pursuant to a registration statement on Form
S-1 (the “Registration Statement”) filed with the Securities and
Exchange Commission (the “SEC”). The selling stockholders intend to
grant the underwriters a 30-day option to purchase up to an
additional 3,000,000 shares of Maravai’s Class A common stock.
Maravai will not receive any proceeds from the sale of shares by
the selling stockholders.
Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are
acting as joint book-running managers and representatives of the
underwriters for the proposed offering.
A registration statement relating to this offering has been
filed with the SEC, but has not yet become effective. The proposed
offering will be made only by means of a prospectus. Copies of the
preliminary prospectus relating to the offering may be obtained
from: Morgan Stanley & Co. LLC, Attn: Prospectus Department,
180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388
or by email at Prospectus_Department@Jefferies.com; or Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, by telephone at 866-471-2526, by
facsimile at 212-902-9316 or by email at
prospectus-ny@ny.email.gs.com.
These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such
offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
novel vaccines and to support research on human diseases. Maravai’s
companies are leaders in providing products and services in the
fields of nucleic acid synthesis and biologic safety testing to
many of the world's leading biopharmaceutical, vaccine,
diagnostics, and cell and gene therapy companies.
Note Regarding Forward-Looking Statements
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following:
- Certain of our products are used by customers in the production
of vaccines and therapies, some of which represent relatively new
and still-developing modes of treatment. Unforeseen adverse events,
negative clinical outcomes, or increased regulatory scrutiny of
these vaccines and therapies and their financial cost may damage
public perception of the safety, utility, or efficacy of these
vaccines and therapies or other modes of treatment and may harm our
customers’ ability to conduct their business. Such events may
negatively impact our revenue and have an adverse effect on our
performance.
- We compete with life science, pharmaceutical and biotechnology
companies who are substantially larger than we are and potentially
capable of developing new approaches that could make our products,
services and technology obsolete.
- We depend on a limited number of customers for a high
percentage of our revenue. If we cannot maintain our current
relationships with customers, fail to sustain recurring sources of
revenue with our existing customers, or if we fail to enter into
new relationships, our future operating results will be adversely
affected.
- We rely on a limited number of suppliers or, in some cases,
sole suppliers, for some of our raw materials and may not be able
to find replacements or immediately transition to alternative
suppliers.
- Such other factors as discussed
throughout the “Risk Factors” section of our Annual Report on Form
10-K filed on March 22, 2021 and our Quarterly Reports on Form 10-Q
filed on May 12 and August 11, 2021, respectively, with the
SEC.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise, except as
required by law.
Contact Information:
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024